Society guideline links: Hypertensive disorders of pregnancy

Introduction — 

This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Hypertension in adults".)

International

●International Society for the Study of Hypertension in Pregnancy (ISSHP): The 2021 classification, diagnosis and management recommendations for international practice (published 2022)

●International Federation of Gynecology and Obstetrics (FIGO): A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia (2021)

●World Health Organization (WHO): Recommendations on antiplatelet agents for the prevention of pre-eclampsia (2021)

●International Society of Hypertension (ISH): Global hypertension practice guidelines (2020)

●WHO: Recommendation on calcium supplementation before pregnancy for the prevention of pre-eclampsia and its complications (2020)

●WHO: Recommendations on drug treatment for non-severe hypertension in pregnancy (2020)

●FIGO: Initiative on pre-eclampsia − A pragmatic guide for first-trimester screening and prevention (2019)

●International Society of Ultrasound in Obstetrics and Gynecology (ISUOG): Practice guidelines on the role of ultrasound in screening for and follow-up of pre-eclampsia (2019)

●WHO: Recommendation on calcium supplementation during pregnancy for prevention of pre-eclampsia and its complications (2018)

●WHO: Recommendations for drug treatment for severe hypertension in pregnancy (2018)

●WHO: Recommendations on a policy of interventionist versus expectant management of severe pre-eclampsia before term (2018)

●FIGO: The FIGO textbook of pregnancy hypertension – An evidence-based guide to monitoring, prevention and management (2016)

●WHO: Recommendations for prevention and treatment of pre-eclampsia and eclampsia (2011)

Canada

●Society of Obstetricians and Gynaecologists of Canada (SOGC): Clinical practice guideline on hypertensive disorders of pregnancy – Diagnosis, prediction, prevention, and management (2022)

●Choosing Wisely Canada: Don't perform routine urinalysis (protein, glucose) at every antenatal visit (in low risk normotensive women) (updated 2021)

●Hypertension Canada: Guidelines for the management of hypertension in pregnancy (2018)

United States

●American College of Obstetricians and Gynecologists (ACOG): Practice advisory – Clinical guidance for the integration of the findings of the Chronic Hypertension and Pregnancy (CHAP) study (2022, reaffirmed 2024)

●American Gastroenterological Association (AGA): Clinical practice update on pregnancy-related gastrointestinal and liver disease (2024)

●American Heart Association (AHA): A scientific statement on opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes (2024)

●California Maternal Quality Care Collaborative (CMQCC): Quality improvement toolkit for improving health care response to hypertensive disorders of pregnancy (2021, revised 2024)

●ACOG and Society for Maternal-Fetal Medicine (SMFM): Committee opinion on low-dose aspirin use during pregnancy (2018, reaffirmed 2023)

●AHA: A scientific statement on anesthetic care of the pregnant patient with cardiovascular disease (2023)

●US Preventive Services Task Force (USPSTF): Final recommendation statement on hypertensive disorders of pregnancy – Screening (2023)

●ACOG and SMFM: Practice advisory for low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality (2021, reaffirmed 2022)

●SMFM: Choosing Wisely – Don't do an inherited thrombophilia evaluation for women with histories of pregnancy loss, fetal growth restriction (FGR), preeclampsia and abruption (2022)

●SMFM: Choosing Wisely – Don't perform routine midtrimester serum biomarker risk stratification for preterm birth or preeclampsia in asymptomatic patients (2022)

●SMFM: Special statement on a quality metric for evaluating timely treatment of severe hypertension (2022)

●SMFM: Special statement on a quality metric for timely postpartum follow-up after severe hypertension (2022)

●SMFM: Statement on antihypertensive therapy for mild chronic hypertension in pregnancy – The Chronic Hypertension and Pregnancy trial (2022)

●SMFM and Preeclampsia Foundation (PF): A report and recommendations of the workshop on preeclampsia (2022)

●AHA: A scientific statement on adverse pregnancy outcomes and cardiovascular disease risk – Unique opportunities for cardiovascular disease prevention in women (2021)

●AHA: A scientific statement on hypertension in pregnancy – Diagnosis, blood pressure goals, and pharmacotherapy (2021)

●USPSTF: Final recommendation statement on aspirin use to prevent preeclampsia and related morbidity and mortality – Preventive medication (2021)

●ACOG: Practice bulletin on gestational hypertension and preeclampsia (2020)

●SMFM: Special statement on a checklist for postpartum discharge of women with hypertensive disorders (2020)

●SMFM: Special statement on checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin (2020)

●ACOG: Practice bulletin on chronic hypertension in pregnancy (2019)

Europe

●European Society of Cardiology (ESC): Guidelines for the management of elevated blood pressure and hypertension (2024)

●European Society of Hypertension (ESH): Position statement for the management of hypertensive disorders in pregnancy (2024)

●ESC and ESH: Position paper for peripartum management of hypertension (2020)

●ESC: Guidelines for the management of cardiovascular diseases during pregnancy (2018)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Guideline on hypertension in pregnancy – Diagnosis and management (2019, updated 2023)

●NICE: Diagnostics guidance on PLGF-based testing to help diagnose suspected preterm pre-eclampsia (2022)

●NICE: Quality standard on hypertension in pregnancy (2013, updated 2019)

●Renal Association (RA): Clinical practice guideline – Pregnancy and renal disease (2019)

Australia–New Zealand

●Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG): Clinical guideline for early pregnancy screening and prevention of preterm preeclampsia and related complications (2024)

●Society of Obstetric Medicine of Australia and New Zealand (SOMANZ): Hypertension in pregnancy guideline (2023)

●Choosing Wisely Australia: Do not do repeat testing for proteinuria in established pre-eclampsia (2017)

Japan

●[In Japanese] Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG): Obstetrics and gynecology clinical practice guidelines – Obstetrics edition (2023)

●[In Japanese] Japan Society for the Study of Hypertension in Pregnancy (JSSHP): Best practice guide for care and treatment of hypertension in pregnancy (2021)

●[In Japanese] Japanese Society of Hypertension (JSH): Hypertension treatment guidelines (2019)

●[In English] JSSHP: Committee report on an outline of the new definition and classification of "Hypertensive Disorders of Pregnancy (HDP)" – A revised statement (2018)

●[In Japanese] JSSHP: Committee report on an outline of the new definition and classification of "Hypertensive Disorders of Pregnancy (HDP)" – A revised statement (2018)